February 2008
In this issue
Inverness Buys Matria for $1.18 Billion

Inverness Medical Innovations, a leading rapid point-of-care diagnostics company will acquire Matria Healthcare in a deal worth $1.18 billion. Marietta, Ga.-based Matria is a provider of health enhancement, disease management and high-risk pregnancy management programs and services. The proposed deal calls for Massachusetts-based Inverness to absorb Matria with Inverness acquiring all outstanding shares of Matria common stock for $39 per share ($6.50 in cash plus $32.50 in convertible preferred stock). The breakdown of the acquisition consists of approximately $900 million for the Matria common stock acquisition and $280 million to cover Matria's outstanding debt.

This will make the 12th acquisition in as many months for Inverness, a maker of home pregnancy tests and fertility monitoring kits. It acquired heart disease diagnostics company Biosite last June for $1.67 billion following a bidding war with Beckman Coulter Inc. In October, Inverness bought Alere, which develops home monitoring systems for patients with chronic diseases, for $302 million, which was quickly followed by the purchase of New Jersey-based ParadigmHealth, which offers disease management services for patients with complex health problems, for $230 million in November.

Based on the company's statement, Inverness plans to consolidate Matria with Alere and ParadigmHealth to form a combined organization focused on the growing health management sector.

In a conference call, Inverness CEO Ron Zwanziger reported that pro forma revenues from these three companies will bring in roughly $500 million, giving Inverness a dominant position in the estimated $1.8 billion health monitoring market. Or, as Zwanziger told a packed house at JP Morgan several weeks ago, "Extending diagnostic testing from disease identification to risk assessment to patient management greatly extends our business potential."


Copyright 2008
Nelson Publishing, 2500 Tamiami Trail North, Nokomis, FL 34275